ArticleMedicine2026
The predictive diagnostic value of combined serum detection of CXCL12, VEGF, and CA125 for endometriosis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers for Endometrial Receptivity: Implications for Infertility, Implantation Failure, and Advances in Diagnosis and Treatment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aims to explore the application value of stromal cell-derived factor (CXCL12), vascular endothelial growth factor (VEGF) and carbohydrate antigen 125 (CA125) in the diagnosis, staging, and clinical manifestations of endometriosis (EMs). A total of 90 patients with EMs (observational group) and 98 with benign ovarian cysts (control group) were enrolled. Comparisons of serum levels of CXCL12, VEGF, and CA125 were made between the 2 groups. Correlations of indicators with visual analog scale score and stages were assessed. Receiver operating characteristic curves were plotted to evaluate the diagnostic value of each indicator in the individual and combined detection of EMs. Serum CXCL12, VEGF, and CA125 were significantly higher in the observational group than in the control group (P < .001). For rASRM stage: IV versus III CXCL12 showed no difference (P = .398), but VEGF and CA125 were elevated (P < .001); III versus I-II, all 3 indicators were elevated (P < .001). For visual analog scale score: severe versus moderate dysmenorrhea, CXCL12 showed no difference (P = .405), but VEGF and CA125 were elevated (P < .001); moderate versus mild dysmenorrhea, all 3 indicators were elevated (P < .001). Combined detection of the 3 indicators yielded higher sensitivity and specificity (area under the curve [AUC]: 0.8823[0.8272, 0.9334]; sensitivity: 84.44%, specificity: 85.71%) than CXCL12 (AUC: 0.8044 [0.7417, 0.863]; sensitivity: 75.56%, specificity: 77.55%), VEGF (AUC: 0.7224 [0.6412, 0.793]; sensitivity: 79.08%, specificity: 52.04%) and CA125 (AUC: 0.6260 [0.5471, 0.6998]; sensitivity: 54.44%, specificity: 68.37%) individually. Serum CXCL12, VEGF, and CA125 levels in EMs patients were significantly different from those in the control group and were correlated with the clinical stage and severity of dysmenorrhea. Compared with individual detection, combined detection has greater clinical value in the diagnosis of EMs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.